ANCA-ASSOCIATED GLOMERULONEPHRITIS
Clinical trials for ANCA-ASSOCIATED GLOMERULONEPHRITIS explained in plain language.
Never miss a new study
Get alerted when new ANCA-ASSOCIATED GLOMERULONEPHRITIS trials appear
Sign up with your email to follow new studies for ANCA-ASSOCIATED GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Matched conditions: ANCA-ASSOCIATED GLOMERULONEPHRITIS
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug STR-P004 aims to tame immune attacks on kidneys
Disease control Not yet recruitingThis early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…
Matched conditions: ANCA-ASSOCIATED GLOMERULONEPHRITIS
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC